首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1831659

免疫肿瘤学市场，规模，占有率，趋势，产业分析报告:治疗方法，各新标的类型，各肿瘤或癌症类型，各地区，2025年～2034年的市场预测

Immuno-Oncology Market Size, Share, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region - Market Forecast, 2025-2034

出版日期: 2025年09月01日 | 出版商:

Polaris Market Research | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

根据 Polaris Market Research 的最新研究，预计到 2034 年，免疫肿瘤市场规模将达到 2,163.4 亿美元。本报告深入分析了当前的市场动态，并对未来的市场成长进行了展望。

免疫肿瘤学被定义为一种先进的治疗方法，它能够增强人体免疫系统识别并精准对抗癌细胞的能力。推动该市场发展的因素是免疫疗法联合疗法的快速普及。联合疗法整合了多种治疗方法，旨在提高疗效、克服抗药性机制并产生更持久的临床反应。由于分子生物学和免疫分析技术的进步，与单一疗法相比，联合疗法能够显着改善患者的治疗效果，因此正日益受到欢迎。

这些联合疗法的成功正在推动研究投资，并扩大其在多种癌症类型中的应用，从而巩固其作为市场发展关键驱动力的地位。

免疫肿瘤学市场也受到日益重视生物标记驱动治疗策略的影响，这些策略能够开发高度标靶的个人化疗法。透过利用基因突变、免疫特征和肿瘤微环境特征等生物标记物，临床医生可以更好地预测患者的治疗反应并据此调整治疗方案。这种精准治疗方法能够优化疗效、最大限度地减少副作用并提高整体治疗耐受性。此外，将生物标记研究整合到药物研发流程中，正在加速技术创新，并推动免疫肿瘤学领域转向更个人化的癌症治疗方案。

免疫肿瘤市场报告亮点

依治疗方法划分，标靶PD-1/PD-L1和CTLA-4的免疫检查点抑制剂预计将在2024年占市场主导地位，收入占有率达57.42%。

基于新型标靶类型，A2AR拮抗剂/CD73i疗法预计在预测期内将以16.1%的复合年增长率增长，这主要得益于其抑制肿瘤中腺苷介导的免疫抑制的能力。

北美地区在先进的医疗保健系统和生物製药创新中心的支持下，预计将在2024年占全球31.27%的市场占有率。

亚太地区免疫肿瘤市场预计到2034年将以16.3%的复合年增长率成长，这主要得益于治疗可近性的提高和医疗保健投资的增加。

全球免疫肿瘤市场的主要参与者包括：安进公司；阿斯特捷利康；百时美施贵宝；礼来公司；葛兰素史克公司；Incyte公司；强生生物技术公司；默克公司；诺华公司；辉瑞公司；罗氏控股公司；赛诺菲；以及武田製药。

免疫肿瘤学(IO)-市场区隔和范围
- 市场定义
免疫肿瘤学(IO)- 市场规模与成长预测
免疫肿瘤学(IO)-价值链分析
市场动态
- 促进因素
  - 非常规和先进治疗技术的日益普及
  - 患有各种癌症的患者数量迅速增加
- 限制因素
  - 免疫疗法的可及性和认知度较低
- 机会分析：免疫肿瘤学市场
  - 患者对改善癌症治疗的需求不断增长
波特五力分析
免疫肿瘤学 (IO) - 公司市占率分析，2024 年
PEST 分析：免疫肿瘤学市场
塑造免疫肿瘤学的五大力量市场
COVID-19 影响分析

第5章免疫肿瘤学市场:治疗方法估计·预测

治疗各类型的市场规模
单株抗体
治疗疫苗
查核点抑制剂
细胞激素

第6章免疫肿瘤学市场:各新标的类型估计·预测

各新标的类型市场规模
IDO1i
LAG-3 CPI
肿瘤溶解性病毒
STING促效剂
TLR促效剂
HDACi
TIL
VEGFi
VEGFi
VEGFi
VEGFi
GITR促效剂
TGF-b回水弯
A2AR拮抗剂/CD73i

第7章免疫肿瘤学市场:各肿瘤或癌症类型估计·预测

各肿瘤或癌症类型的市场规模
黑色素瘤
非小细胞肺癌
肾细胞癌症
头颈椎癌症
膀胱癌
传统何杰金氏淋巴瘤
merukeru细胞癌症
其他的癌症类型

第8章免疫肿瘤学市场:各地区估计·预测

各地区市场规模
北美
- 美国
- 加拿大
欧洲
- 法国
- 德国
- 义大利
- 西班牙
- 英国
- 奥地利
- 荷兰
- EU的残余
亚太地区
- 中国
- 印度
- 日本
- 印尼
- 韩国
- 马来西亚
- 亚太地区
南美
- 巴西
- 墨西哥
- 阿根廷
- 其他的南美各国
中东·非洲
- 以色列
- 沙乌地阿拉伯
- 南非
- 阿拉伯联合大公国
- 其他中东和非洲

第9章竞争情形

策略性架构
COVID-19大流行病中主要企业采用了的策略
竞争环境
合併·收购分析

第10章企业简介

Bristol Myers Squibb
Merck & Co.
AstraZeneca
Roche Holding AG
Pfizer Inc.
Incyte Corporation
Amgen, Inc.
Eli Lilly and Company
GlaxoSmithKline Plc
Janssen Biotech, Inc
Novartis AG
Sanofi
Takeda Pharmaceuticals

简介目录图表

Product Code: PM1083

The Immuno-oncology market size is expected to reach USD 216.34 billion by 2034, according to a new study by Polaris Market Research. The report "Immuno-Oncology Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches (Monoclonal Antibodies, Therapeutic Vaccines), By Novel Target Type, By Tumor or Cancer Type, By Region; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Immuno-oncology can be defined as an advanced therapeutic approach that empowers the body's immune system to recognize and combat cancer cells with precision. This market is driven by the rapid adoption of combination immunotherapies, which integrate multiple treatment modalities to enhance efficacy, overcome resistance mechanisms, and provide more durable clinical responses. These approaches are gaining traction as they deliver improved patient outcomes compared to monotherapies, supported by ongoing advancements in molecular biology and immune profiling. The increasing success of such combinations is driving research investment and expanding the scope of application across various cancer types, reinforcing their role as a cornerstone of the market's evolution.

The immuno-oncology market is further influenced by the growing focus on biomarker-driven treatment strategies, enabling the development of highly targeted and personalized therapies. Clinicians can better predict patient response and tailor treatments accordingly by leveraging biomarkers such as genetic mutations, immune signatures, and tumor microenvironment characteristics. This precision-focused approach optimizes therapeutic effectiveness and also minimizes adverse effects, improving overall treatment tolerability. Additionally, the integration of biomarker research into drug development pipelines is accelerating innovation and enabling a shift toward more individualized cancer care solutions within the immuno-oncology landscape.

Immuno-Oncology Market Report Highlights

In terms of treatment approaches, the checkpoint inhibitors led with 57.42% revenue share in 2024, driven by their durable clinical responses across cancers through PD-1/PD-L1 and CTLA-4 targeting.

Based on novel target type, the A2AR antagonist/CD73i therapies segment is expected to register the highest CAGR of 16.1% during the forecast period by disrupting adenosine-mediated immunosuppression in tumors.

In 2024, North America dominated with 31.27% global share, supported by advanced healthcare systems and biopharma innovation hubs.

The Asia Pacific Immuno-Oncology Market would report a CAGR of 16.3% by 2034, fueled by rising treatment access and healthcare investments.

A few global key Immuno-Oncology Market players include Amgen, Inc.; AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; GlaxoSmithKline Plc; Incyte Corporation; Janssen Biotech, Inc; Merck & Co.; Novartis AG; Pfizer Inc.; Roche Holding AG; Sanofi; and Takeda Pharmaceuticals.

Polaris Market Research has segmented the Immuno-Oncology Market report on the basis of treatment approaches, novel target type, tumor or cancer type, and region:

By Treatment Approaches Outlook (Revenue, USD Billion, 2020-2034)

Monoclonal Antibodies

Therapeutic Vaccines

Checkpoint Inhibitors

Cytokines

By Novel Target Type Outlook (Revenue, USD Billion, 2020-2034)

IDO1i

LAG-3 CPI

Oncolytic Virus

STING Agonist

TLR Agonist

HDACi

TIL

VEGFi

MEKi

TIGIT

CPI

GITR Agonist

TGF-b trap

A2AR Antagonist/CD73i

By Tumor or Cancer Type Outlook (Revenue, USD Billion, 2020-2034)

Melanoma

Non-Small Cell Lung Cancer

Renal Cell Carcinoma

Head, Face & Neck Cancer

Bladder Cancer

Classical Hodgkin's Lymphoma

Merkel Cell Carcinoma

Other Cancer Types

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Vietnam

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa

Chapter 1. Introduction

1.1 Report Description

Chapter 2. Research Methodology Overview

2.1 Research Process
- 2.1.1 Information procurement
- 2.1.2 Purchased database:
- 2.1.3 Polaris Market Research's internal database
2.2 Research Methodology
2.3 Research Scope & Assumptions
2.4 List of Data Sources

Chapter 3. Executive Summary

3.1 Market Snapshot - Key Takeaways
3.2 Immuno-Oncology (IO) regional market place: Key takeaways

Chapter 4. Immuno-Oncology (IO) Market Insights

4.1 Immuno-Oncology (IO) - Market segmentation & scope
- 4.1.1 Market definitions
4.2 Immuno-Oncology (IO) - Market size and growth prospects
4.3 Immuno-Oncology (IO) - Value chain analysis
4.4 Market Dynamics
- 4.4.1 Drivers
  - 4.4.1.1 Increasing introduction of unconventional and advanced treatment techniques
  - 4.4.1.2 Rapidly growing population of various cancer infected patients
- 4.4.2 Restraints
  - 4.4.2.1 Limited access and awareness about immunotherapy
- 4.4.3 Opportunity analysis: Immunology-oncology market
  - 4.4.3.1 Increasing demand for improved cancer care by patients
4.5 Porter's Five Forces Analysis
4.6 Immuno-Oncology (IO) - Company Market Share Analysis, 2024
4.7 PEST Analysis: Immuno-Oncology Market
4.8 Five forces shaping the immuno-oncology market
4.9 COVID-19 Impact Analysis

Chapter 5. Immuno-Oncology Market Estimates and Forecast, by Treatment Approaches

5.1 Market size by treatment type
5.2 Monoclonal Antibodies
- 5.2.1 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034
5.3 Therapeutic Vaccines
- 5.3.1 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034
5.4 Checkpoint Inhibitors
- 5.4.1 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034
5.5 Cytokines
- 5.5.1 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034

Chapter 6. Immuno-Oncology Market Estimates and Forecast, by Novel Target Type

6.1 Market size by novel target type
6.2 IDO1i
- 6.2.1 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034
6.3 LAG-3 CPI
- 6.3.1 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034
6.4 Oncolytic virus
- 6.4.1 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034
6.5 STING agonist
- 6.5.1 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034
6.6 TLR agonist
- 6.6.1 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034
6.7 HDACi
- 6.7.1 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034
6.8 TIL
- 6.8.1 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034
6.9 VEGFi
- 6.9.1 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034
6.10 MEKi
- 6.10.1 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034
6.11 TIGIT
- 6.11.1 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034
6.12 CPI
- 6.12.1 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034
6.13 GITR agonist
- 6.13.1 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034
6.14 TGF-b trap
- 6.14.1 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034
6.15 A2AR antagonist/CD73i
- 6.15.1 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034

Chapter 7. Immuno-Oncology Market Estimates and Forecast, by Tumor or Cancer Type

7.1 Market size by tumor or cancer type
7.2 Melanoma
- 7.2.1 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034
7.3 Non-small cell lung cancer
- 7.3.1 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034
7.4 Renal cell carcinoma
- 7.4.1 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034
7.5 Head, face & neck cancer
- 7.5.1 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034
7.6 Bladder cancer
- 7.6.1 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034
7.7 Classical hodgkin's lymphoma
- 7.7.1 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034
7.8 Merkel cell carcinoma
- 7.8.1 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034
7.9 Other cancer types
- 7.9.1 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034

Chapter 8. Immuno-Oncology Market Estimates and Forecast, by Region

8.1 Market size by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 France
- 8.3.2 Germany
- 8.3.3 Italy
- 8.3.4 Spain
- 8.3.5 UK
- 8.3.6 Austria
- 8.3.7 Netherlands
- 8.3.8 Rest of EU
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 India
- 8.4.3 Japan
- 8.4.4 Indonesia
- 8.4.5 South Korea
- 8.4.6 Malaysia
- 8.4.7 RoAPAC
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of LATAM
8.6 Middle East & Africa
- 8.6.1 Israel
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 UAE
- 8.6.5 Rest of Middle East & Africa

Chapter 9. Competitive Landscape

9.1 Strategy framework
9.2 Strategies Adopted By Major Players During COVID-19 Pandemic
9.3 Competitive Environment
9.4 Merger & Acquisition Analysis

Chapter 10. Company Profiles

10.1 Bristol Myers Squibb
- 10.1.1 Company Overview
- 10.1.2 Financial Performance (Revenue)
- 10.1.3 Product Benchmarking
- 10.1.4 Recent Developments
10.2 Merck & Co.
- 10.2.1 Company Overview
- 10.2.2 Financial Performance (Revenue)
- 10.2.3 Product Benchmarking
- 10.2.4 Recent Developments
10.3 AstraZeneca
- 10.3.1 Company Overview
- 10.3.2 Financial Performance (Revenue)
- 10.3.3 Product Benchmarking
- 10.3.4 Recent Developments
10.4 Roche Holding AG
- 10.4.1 Company Overview
- 10.4.2 Financial Performance (Revenue)
- 10.4.3 Product Benchmarking
- 10.4.4 Recent Developments
10.5 Pfizer Inc.
- 10.5.1 Company Overview
- 10.5.2 Financial Performance (Revenue)
- 10.5.3 Product Benchmarking
- 10.5.4 Recent Developments
10.6 Incyte Corporation
- 10.6.1 Company Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Benchmarking
- 10.6.4 Recent Developments
10.7 Amgen, Inc.
- 10.7.1 Company Overview
- 10.7.2 Financial Performance (Revenue)
- 10.7.3 Product Benchmarking
- 10.7.4 Recent Developments
10.8 Eli Lilly and Company
- 10.8.1 Company Overview
- 10.8.2 Financial Performance (Revenue)
- 10.8.3 Product Benchmarking
- 10.8.4 Recent Developments
10.9 GlaxoSmithKline Plc
- 10.9.1 Company Overview
- 10.9.2 Financial Performance (Revenue)
- 10.9.3 Product Benchmarking
- 10.9.4 Recent Developments
10.10 Janssen Biotech, Inc
- 10.10.1 Company Overview
- 10.10.2 Jonson & Johnson Financial Performance (Revenue)
- 10.10.3 Product Benchmarking
- 10.10.4 Recent Developments
10.11 Novartis AG
- 10.11.1 Company Overview
- 10.11.2 Financial Performance (Revenue)
- 10.11.3 Product Benchmarking
- 10.11.4 Recent Developments
10.12 Sanofi
- 10.12.1 Company Overview
- 10.12.2 Financial Performance (Revenue)
- 10.12.3 Product Benchmarking
- 10.12.4 Recent Developments
10.13 Takeda Pharmaceuticals
- 10.13.1 Company Overview
- 10.13.2 Financial Performance (Revenue)
- 10.13.3 Product Benchmarking
- 10.13.4 Recent Developments

简介目录图表

List of Tables

Table 1 Global Immuno-Oncology market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 2 Drivers and inhibitors for global immuno-oncology market:
Table 3 Restraints for global immuno-oncology market:
Table 4 Global Immuno-Oncology monoclonal antibodies treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 5 Global Immuno-Oncology therapeutic vaccines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 6 Global Immuno-Oncology checkpoint inhibitors treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 7 Global Immuno-Oncology cytokines treatment market estimates & forecasts by region, 2021-2034, (USD Billion)
Table 8 Global Immuno-Oncology market estimates & forecasts for IDO1i target by region, 2021-2034, (USD Billion)
Table 9 Global Immuno-Oncology market estimates & forecasts for LAG-3 CPI target by region, 2021-2034, (USD Billion)
Table 10 Global Immuno-Oncology market estimates & forecasts for Oncolytic virus target by region, 2021-2034, (USD Billion)
Table 11 Global Immuno-Oncology market estimates & forecasts for STING agonist target by region, 2021-2034, (USD Billion)
Table 12 Global Immuno-Oncology market estimates & forecasts for TLR agonist target by region, 2021-2034, (USD Billion)
Table 13 Global Immuno-Oncology market estimates & forecasts for HDACi target by region, 2021-2034, (USD Billion)
Table 14 Global Immuno-Oncology market estimates & forecasts for TIL target by region, 2021-2034, (USD Billion)
Table 15 Global Immuno-Oncology market estimates & forecasts for VEGFi target by region, 2021-2034, (USD Billion)
Table 16 Global Immuno-Oncology market estimates & forecasts for MEKi target by region, 2021-2034, (USD Billion)
Table 17 Global Immuno-Oncology market estimates & forecasts for TIGIT target by region, 2021-2034, (USD Billion)
Table 18 Global Immuno-Oncology market estimates & forecasts for CPI target by region, 2021-2034, (USD Billion)
Table 19 Global Immuno-Oncology market estimates & forecasts for GITR agonist target by region, 2021-2034, (USD Billion)
Table 20 Global Immuno-Oncology market estimates & forecasts for TGF-b trap target by region, 2021-2034, (USD Billion)
Table 21 Global Immuno-Oncology market estimates & forecasts for A2AR antagonist/CD73i target by region, 2021-2034, (USD Billion)
Table 22 Global Immuno-Oncology market estimates & forecasts for melanoma cancer by region, 2021-2034, (USD Billion)
Table 23 Global Immuno-Oncology market estimates & forecasts for non-small cell lung cancer by region, 2021-2034, (USD Billion)
Table 24 Global Immuno-Oncology market estimates & forecasts for renal cell carcinoma cancer by region, 2021-2034, (USD Billion)
Table 25 Global Immuno-Oncology market estimates & forecasts for head, face & neck cancer by region, 2021-2034, (USD Billion)
Table 26 Global Immuno-Oncology market estimates & forecasts for bladder cancer by region, 2021-2034, (USD Billion)
Table 27 Global Immuno-Oncology market estimates & forecasts for classical hodgkin's lymphoma cancer by region, 2021-2034, (USD Billion)
Table 28 Global Immuno-Oncology market estimates & forecasts for merkel cell carcinoma cancer by region, 2021-2034, (USD Billion)
Table 29 Global Immuno-Oncology market estimates & forecasts for other cancer types by region, 2021-2034, (USD Billion)
Table 30 North America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 31 North America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 32 North America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 33 North America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 34 U.S. Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 35 U.S. Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 36 U.S. Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 37 Canada Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 38 Canada Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 39 Canada Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 40 Europe Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 41 Europe Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 42 Europe Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 43 Europe Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 44 France Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 45 France Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 46 France Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 47 Germany Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 48 Germany Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 49 Germany Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 50 Italy Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 51 Italy Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 52 Italy Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 53 Spain Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 54 Spain Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 55 Spain Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 56 UK Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 57 UK Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 58 UK Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 59 Austria Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 60 Austria Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 61 Austria Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 62 Netherlands Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 63 Netherlands Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 64 Netherlands Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 65 Rest of EU Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 66 Rest of EU Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 67 Rest of EU Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 68 Asia Pacific Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 69 Asia Pacific Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 70 Asia Pacific Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 71 Asia Pacific Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 72 China Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 73 China Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 74 China Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 75 India Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 76 India Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 77 India Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 78 Japan Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 79 Japan Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 80 Japan Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 81 Indonesia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 82 Indonesia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 83 Indonesia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 84 South Korea Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 85 South Korea Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 86 South Korea Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 87 Malaysia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 88 Malaysia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 89 Malaysia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 90 RoAPAC Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 91 RoAPAC Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 92 RoAPAC Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 93 Latin America Immuno-Oncology market estimates & forecasts by Country, 2021-2034, (USD Billion)
Table 94 Latin America Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 95 Latin America Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 96 Latin America Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 97 Brazil Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 98 Brazil Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 99 Brazil Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 100 Mexico Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 101 Mexico Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 102 Mexico Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 103 Argentina Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 104 Argentina Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 105 Argentina Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 106 Rest of LATAM Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 107 Rest of LATAM Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 108 Rest of LATAM Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 109 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 110 Middle East & Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 111 Middle East & Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 112 Middle East & Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 113 Israel Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 114 Israel Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 115 Israel Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 116 Saudi Arabia Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 117 Saudi Arabia Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 118 Saudi Arabia Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 119 South Africa Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 120 South Africa Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 121 South Africa Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 122 UAE Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 123 UAE Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 124 UAE Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)
Table 125 RoMEA Immuno-Oncology market estimates & forecasts by treatment type, 2021-2034, (USD Billion)
Table 126 RoMEA Immuno-Oncology market estimates & forecasts by novel target type, 2021-2034, (USD Billion)
Table 127 RoMEA Immuno-Oncology market estimates & forecasts by tumor type, 2021-2034, (USD Billion)

List of Figures

Figure 1. Research process
Figure 2. Information procurement
Figure 3. Global Immuno-Oncology Market, 2021-2034 (USD Billion)
Figure 4. Porter's Five Forces Analysis
Figure 5. PEST Analysis: Immuno-Oncology Market
Figure 6. Immuno-Oncology market share by treatment type/process, 2021-2034
Figure 7. Immuno-Oncology market share by novel target, 2024 & 2034
Figure 8. Immuno-Oncology market share by tumour or cancer type, 2021-2034
Figure 9. Immuno-Oncology market share by region, 2024 & 2034

02-2729-4219

+886-2-2729-4219

License/价格

免疫肿瘤学市场，规模，占有率，趋势，产业分析报告:治疗方法，各新标的类型，各肿瘤或癌症类型，各地区，2025年～2034年的市场预测